BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2551 related articles for article (PubMed ID: 28975890)

  • 21. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
    Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
    Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
    Minardi D; Lucarini G; Filosa A; Milanese G; Zizzi A; Di Primio R; Montironi R; Muzzonigro G
    Int J Immunopathol Pharmacol; 2008; 21(2):447-55. PubMed ID: 18547492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue-based molecular markers for renal cell carcinoma.
    Rink M; Chun FK; Robinson B; Sun M; Karakiewicz PI; Bensalah K; Fisch M; Scherr DS; Lee RK; Margulis V; Shariat SF
    Minerva Urol Nefrol; 2011 Dec; 63(4):293-308. PubMed ID: 21996985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
    Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
    Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases.
    Maas M; Kurcz A; Hennenlotter J; Scharpf M; Fend F; Walz S; Stühler V; Todenhöfer T; Stenzl A; Bedke J; Rausch S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.
    Gasinska A; Jaszczynski J; Adamczyk A; Janecka-Widła A; Wilk W; Cichocka A; Stelmach A
    Folia Histochem Cytobiol; 2018; 56(4):195-206. PubMed ID: 30569446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status and future directions of molecular markers in renal cell carcinoma.
    Rini BI
    Curr Opin Urol; 2006 Sep; 16(5):332-6. PubMed ID: 16905977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical co-expression of PAX2 and CAIX predicts better prognosis in clear cell renal cell carcinoma after nephrectomy: A retrospective observational study.
    Shao H; Liao Y; Xiang M; Hu D; Liu S
    Cell Mol Biol (Noisy-le-grand); 2024 Jun; 70(6):129-134. PubMed ID: 38836670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.
    Hoffmann NE; Sheinin Y; Lohse CM; Parker AS; Leibovich BC; Jiang Z; Kwon ED
    Cancer; 2008 Apr; 112(7):1471-9. PubMed ID: 18260086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.
    Sandlund J; Oosterwijk E; Grankvist K; Oosterwijk-Wakka J; Ljungberg B; Rasmuson T
    BJU Int; 2007 Sep; 100(3):556-60. PubMed ID: 17608827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
    Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.
    Schultz L; Chaux A; Albadine R; Hicks J; Kim JJ; De Marzo AM; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
    Am J Surg Pathol; 2011 Oct; 35(10):1549-56. PubMed ID: 21881486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
    Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
    Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.
    Saeednejad Zanjani L; Madjd Z; Abolhasani M; Andersson Y; Rasti A; Shariftabrizi A; Asgari M
    Exp Mol Pathol; 2017 Oct; 103(2):218-228. PubMed ID: 29050853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
    Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
    BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
    Gupta R; Balzer B; Picken M; Osunkoya AO; Shet T; Alsabeh R; Luthringer D; Paner GP; Amin MB
    Am J Surg Pathol; 2009 Feb; 33(2):241-7. PubMed ID: 18941400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.
    Müller T; Tolkach Y; Stahl D; Steiner S; Hauser S; Ellinger J; Rabien A; Ralla B; Jung K; Stephan C; Kristiansen G
    Clin Genitourin Cancer; 2019 Feb; 17(1):e167-e175. PubMed ID: 30448104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 128.